Introduction
There exists in excess of 20 years experience of high-dose chemotherapy and auto-SCT to support haematopoietic recovery since the initial reports of its efficacy. 1 In the intervening years, there has been in excess of 500 published reports on the use of auto-SCT in the treatment of multiple myeloma (MM), with nearly 15 000 patients undergoing auto-SCT between 1973 and 2003. 2 Originally a procedure of 'last resort', for younger patients (o65 years) with MM, it is the current standard of care following induction therapy. 3 Various studies have shown that maximal benefit is seen in patients who achieve complete response (CR) following treatment. 4, 5 There is now evidence from several randomized trials that those patients who undergo an auto-SCT as part of their initial management will have an increased EFS and OS compared with those receiving conventional chemotherapy. 5, 6 In essence, four pivotal randomized studies have been published comparing conventional chemotherapy with a high-dose approach as first-line therapy for newly diagnosed Durie and Salmon stage II/III MM. The IFM90 study demonstrated that EFS and OS) were significantly longer in auto-SCT. 7, 8 The MRC VII trial also demonstrated significantly longer EFS and OS in the auto-SCT arm with a 32-month and 54-month median EFS and OS, respectively, compared with 20 months and 42 months for conventional chemotherapy. 6 These results are consistent with those of a population-based historical case-control study from the Nordic Myeloma Study Groups. 9 The French MAG91 study showed a significant prolongation of EFS but not of OS, whereas in the Spanish PETHEMA trial there was no significant difference in either EFS or OS but an improvement in the post-auto-SCT CR rate. 10, 11 Improvements in SCT care over the years have progressively affected the TRM associated with high-dose therapy and auto-SCT, as demonstrated in successive EBMT registry studies. 5 Furthermore, following its inception in 1997, the British Society of Blood and Marrow Transplantation (BSBMT) set up a clinical governance programme, undertaking a number of initiatives to examine clinical outcomes from SCT applied across all disease entities through retrospective analysis. Such a study comparing the outcomes of auto-SCT in Hodgkin's disease and allo-SCT in CML in BSBMT centres with the European Group for Blood and Marrow Transplantation (EBMT) was conducted as a 'benchmarking' study. 12 Therefore, we undertook a comparative outcome assessment of patients with MM undergoing auto-SCT in the United Kingdom/Ireland intwo comparative and contrasting years representing the 1990s and 2000s, to demonstrate continuing or improving standards of care resulting in appropriate clinical outcomes. The objective of this comparative study was to compare the TRM and OS in patients undergoing auto-SCT as clinical management of their MM, with the outcomes from centres being reported to the EBMT registry, analysing trends in patient-specific demographics, with particular reference to age.
Patients and methods
All patients with MM who underwent an auto-SCT as part of their initial disease management following combination induction chemotherapy in 1999 and 2005, reported from all UK centres, were identified from the BSBMT database as being eligible for this analysis. Data were sourced from MED A input data contained in the BSBMT database. Patient-, disease-, and transplant-related variables were collected according to the data entries in the BSBMT database on the basis of MED A forms, including tracking incomplete data entries from participating centres. For the purpose of the 'benchmarking' exercise, EBMT registry-derived data for the corresponding years and non-UK patient groups were identified to correlate the clinical outcomes in this analysis.
Outcome measures
The response criteria of the EBMT were used. 13 Clinical response was defined as CR (CR: no measurable paraprotein, no detectable Bence-Jones proteinuria and p5% plasma cells in BM) and partial response (PR: X50% reduction in paraprotein or X50% reduction in urinary light chain excretion compared with the pretreatment baseline). Stable disease (SD: o50% reduction in paraprotein with stable clinical state) and progressive disease (PD: progressive clinical symptoms and/or the appearance or progression of new bone lesions and/or an increase in the paraprotein level by X25%) were deemed as treatment failure. The response rate at D þ 100 after auto-SCT was determined and compared with the status at transplant. Relapse was determined as the time point associated with the onset of clinical recurrence or disease progression. TRM was defined as mortality related to the procedure, and death without progression is considered as the event.
In addition to patient-and disease-specific variables, the analysis also considered the influence of year of transplant (1999 vs 2005) , time from diagnosis to auto-SCT, number of lines of therapy before auto-SCT, conditioning regimen (Melphalan 200 mg/m 2 vs 'other') and disease response (response rate and freedom-from-disease progression) on auto-SCT outcome.
Statistical analysis
The Kaplan-Meier product-limit estimator was used to estimate the median and range of the follow-up time. Univariate probabilities of PFS and survival were calculated using the Kaplan-Meier estimator. Probabilities of non-relapse mortality (NRM) and relapse were calculated using cumulative incidence curves to accommodate competing risks. Relapse was used as competing risk for NRM, and NRM as the competing risk for relapse. Confidence intervals (CI) of 95% for all probabilities and P-values of pairwise comparisons were derived from pointwise estimates and calculated using standard techniques. NRM, relapse, PFS and survival after auto-SCT were evaluated in multivariate analyses using competing risk analysis to identify patient-, disease-and transplant-related variables prognostic of outcomes. Multivariate analysis considered key variables with the assumption of proportional hazards for each factor in the Cox model (tested using timedependent covariates). When this indicated differential effects over time (non-proportional hazards), models were constructed breaking the post transplant time course into two periods, using the maximized partial likelihood method to find the most appropriate breakpoint. Interactions between covariates were tested before stepwise modelling. After modelling time-varying effects and interactions, the final multivariate model was built using a forward stepwise model selection approach. Factors significantly associated with the outcome variable at a 5% level were retained in the final model. All P-values were two-sided. Response rate, durability of response and survival Formal disease assessment at D þ 100 was performed in 93.6% of the study cohort. CR was reported in 44%, with CR being maintained from induction in 19.3% and being achieved after auto-SCT in 24.7%. When considered by year of transplant, a trend to more CRs post auto-SCT was reported in 1999 compared with 2005 (53 vs 46%, P ¼ 0.14), although an improved conversion to CR post auto-SCT (34 vs 24%, P ¼ 0.013), especially PR-CR (47 vs 34%, P ¼ 0.016), was noted. Table 2) .
Results

Patient and transplant characteristics
The 4-year PFS for the cohort was 27% (CI 23-31%). However, the 4-year PFS was significantly lower for those transplanted in 2005 compared with those transplanted in 1999 (16% (CI 9, 26) vs 36% (CI 29, 43); P ¼ 0.0012; Figure 2a ). An impact of the planned use of post-auto-SCT maintenance was demonstrable with improved median PFS (2.9 years vs 2.2 years, P ¼ 0.0249). In a univariate analysis, the age at diagnosis (P ¼ 0.024), status at transplant (P ¼ 0.025), year of transplant (P ¼ 0.0012) and the use of maintenance therapy (0.0249) influenced the PFS (Table 2) . In a multivariate analysis, only the year of auto-SCT (P ¼ 0.001) and status at auto-SCT (P ¼ 0.02) significantly affected PFS (Table 3) . Figure 2b) . In a univariate analysis, the age at transplant (P ¼ 0.038), b 2 -microglobulin level at diagnosis (P ¼ 0.0096) and the status at auto-SCT (P ¼ 0.0337) predicted OS (Table 2) . In a multivariate analysis (Table 3) , time to transplant (P ¼ 0.015) and b 2 -microglobulin level at diagnosis (P ¼ 0.014) significantly affected OS, with a trend seen in association with status at auto-SCT (P ¼ 0.048).
UK/Ireland and European 'benchmarking' comparative analysis
To compare the outcomes of patents with MM undergoing auto-SCT in the United Kingdom and Europe and in the 2-year cohorts (year 1999 and 2005), we sourced outcome data from the EBMT registry of non-UK patients Table 1 . The cohorts were matched in terms of age at diagnosis, age at auto-SCT, sex and b 2 -microglobulin , but differences in the proportion of Durie-Salmon II and III disease were noted in the EBMT cohort compared with the UK cohort (Po0.001), and more patients were transplanted with mixed response/stable disease and progressive disease in the EBMT cohort compared with the UK cohort (Po0.001; Table 1 ). Although the reduction in NRM between 1999 and 2005 in the EBMT series is statistically significant (4-year NRM: 9% CI 8, 11 vs 6% CI 5, 8; P ¼ 0.01), the corresponding data sets with the BSBMT are not significantly different (Figures 3a and b) . In keeping with the difference in the 4-year RR between the year cohorts of the BSBMT series, the EBMT data set demonstrated a significant increase in RR in 2005 compared with 1999 (39% CI 35, 40 vs 87% CI 84, 90; P ¼ 0.0001), although not significantly different compared with the BSBMT data set (Figures 3c and d) . There was a significant reduction in the 4-year PFS in the EBMT 2005 data set compared with 1999 (53% CI 50, 56 vs 6% CI 4, 9; P ¼ 0.0001). When compared collectively, EBMT 1999 demonstrated the best PFS, although no yearof-transplant effect could be demonstrated on the 4-year OS rates in the EBMT 1999 and 2005 cohorts (62% CI 58, 65 vs 57% CI 50, 63; P ¼ 0.760; Figures 4a and b) . Cumulative hazards were calculated for PFS in both data sets, as illustrated in Figure 4c . The cumulative hazard curves for PFS demonstrate a broadly linear hazard in the BSBMT data set and a nonlinear hazard in the EBMT data set. This demonstrates either a different relapse pattern or possibly a different reporting pattern between the data sets and, as such, for the purpose of proportional hazard calculations using the Cox model (and consequent P-value), these have been restricted to the part of the curve for which the hazards seem to be approximately proportional.
Discussion
High-dose chemotherapy together with auto-SCT is currently considered to be standard first-line consolidation therapy in MM in patients deemed fit, as a result of Outcome analysis for auto-SCT in myeloma G Cook et al extensive clinical experience and randomized controlled study data. 1, 5, 6 As a result of improvements in supportive care and changing induction therapy to deliver better preauto-SCT disease control, we undertook a comparative outcome analysis of patients with MM undergoing auto-SCT in the United Kingdom/Ireland and European Union in two comparative and contrasting years (1999 and 2005) to determine any effect on clinical outcomes. The results presented in this study demonstrate the current use of intensive antimyeloma therapy and raises several issues.
The primary aim of this study was to compare the safety and efficacy of auto-SCT in 2-year cohorts representing consecutive decades in the UK/Ireland national database, while simultaneously comparing similar data sets with the EBMT database as a 'benchmarking' exercise. This type of analysis was performed to provide an outcome measurement in a single country compared with the 'expected' outcomes of an international data registry, as previously performed for CML and Hodgkin's disease. 12 The results clearly illustrate that for patients deemed fit to undergo intensive therapy a 4-year OS of B60% can be demonstrated. It has recently been reported that with the introduction of novel agents in the management of myeloma, improvement in OS can be demonstrated, especially in patients treated more intensively. 14, 15 These studies demonstrated improved OS between the decades, surrounding the introduction of novel agents. We did not demonstrate an improved OS between 1999 and 2005, although, with follow-up in the 2005 cohort being limited, the true impact of post transplant relapse salvage therapy is yet to take effect. In the univariate analysis of factors affecting OS, when the year of transplant was considered, those transplanted in 1999 demonstrated a median OS of 5.2 years, whereas those transplanted in 2005 had not reached their median OS. The evidence in this analysis once again demonstrates the durability of auto-SCT as consolidative strategy in MM. MM has a peak incidence in the 70-year age group, and previous studies have suggested that age at presentation and at transplant can have an impact on OS. 16 More recently, a population-based projected analysis suggested that the best improvement in OS is in fact seen in the younger age group, although not based on a specific treatment intervention, 17 and a study specifically examining the effect of auto-SCT in patients aged 40 years and below did not confer a significant effect on OS in relation to auto-SCT. 18 In our study, neither defining an age cutoff above and below the median (P ¼ 0.091) nor defining it as a continuous variable (P ¼ 0.084; Cox analysis) could demonstrate an effect on OS in univariate or multivariate analysis. Outcome analysis for auto-SCT in myeloma G Cook et al
This analysis demonstrates a subtle improvement in NRM in the UK/Ireland population, a feature that is more definitive in the EBMT cohorts with NRM being reported as 6% in both BSBMT and EBMT cohorts in 2005. This is similar to that reported in previous studies. 6, 19, 20 The primary reason for treatment failure was disease progression, and a year effect is demonstrated indicating an increased RR, reduced PFS and reduced TTNT in the BSBMT cohort. In the benchmarking analysis, the increased RR and reduced PFS between 1999 and 2005 were still evident. The reason for the surprising decline in PFS in those transplanted in 2005 compared with 1999 is unclear. More CRs were generated in 1999, largely through CR conversion (although no difference in conditioning regimen is noted in either year or country cohorts), which may explain the improved PFS in 1999 and is in keeping with previously published data that suggest that CR before auto-SCT is less important than achieving a CR. 21 Nonetheless, the planned use of maintenance therapy post auto-SCT was significantly associated with better PFS (P ¼ 0.0249), which was mostly IFN-a. Such an effect of maintenance has been demonstrated to occur in relation to PFS but not OS. 22 Because of the limitations of our data set, it was not possible to discern an effect of differing induction regimens in this analysis, although published data in fact suggest that improved CR rates are more evident with the introduction of novel agents throughout the 2000s. [23] [24] [25] [26] Alternatively, it is possible that this represents a technical issue of data collection and verification, as defining relapse as time points can be less definitive than defining death, features that underpin the calculation of PFS and OS, respectively. However, the reduced TTNT in 2005 compared with 1999 suggests that, in fact, the reduced time to relapse is clinically evident. The EBMT/International BMT registry introduced criteria in 1998, which were updated and expanded by the International Working Group in 2006. 13, 27 By clarifying inconsistencies in the earlier criteria, the revised criteria aimed to make confirmation of response and disease progression easier to perform by placing emphasis on time to event and duration of response as critical end points. It is possible that, given the defined years of assessment in our cohort, the altered criteria could explain the difference in PFS reporting, although the possibility of explaining the clinical intervention parameter of TTNT is unlikely. It is unlikely to represent a centre effect, as the same centres contributed data for both 1999 and 2005 cohorts. Furthermore, concerns over the 'CR penalty', in which dependency on transition from an immunofixation negative to a positive state is a nonclinically significant progressive disease stage, highlights the limitation of using such a parameter to determine PFS. The expanded criteria by the IMWG indicate that progressive disease for purposes of estimating PFS occurs only if there is an increase in paraprotein to the level required for all Outcome analysis for auto-SCT in myeloma G Cook et al other response categories. 28 In our series, this is less likely to cause an impact, given the fact that higher CR rates post auto-SCT were reported in the 1999 cohort. It is equally unlikely to represent a centre effect, as the same centres contributed data for both 1999 and 2005 cohorts. However, the difference in TTNT may relate to altered clinical practice in relation to progressive disease post auto-SCT. In the 1990s, salvage regimens comprised of chemotherapy combinations only (for example, ABCM, VAD-like hybrids), and this may have affected clinical decision making as to when to commence therapy, for example, clinical relapse versus biochemical relapse. In the 2000s, with the advent of novel agents, it is possible that there was a paradigm shift in relapse management such that earlier clinical intervention (based on biochemical determination of progressive disease without evidence of tissue infiltration or dysfunction) with newer agents was observed. This would result in early reporting of relapse (reduced PFS) and salvage therapy introduction (reduced TTNT). However, this cannot be clarified because of the limitations in the data sets available from the United Kingdom and European Union.
The results of this study demonstrate similar patterns of patient-and disease-response parameters, with improved procedural safety (NRM) and survival. The safe deliverability of such treatment in the United Kingdom/Ireland is comparable to that provided in other countries within the EU. The demonstrable difference in durability of auto-SCT-induced response remains to be explained. The results of this study confirm that myeloma care in the United Kingdom/Ireland demonstrates similar outcomes with that reported in the European Union, with regard to high-dose therapy and autologous stem cell rescue. As yet, there is no significant improvement in survival in relation to salvage therapy with novel agents post relapse that could be demonstrated in this cohort analysis, although this may reflect the more limited follow-up of the 2005 cohort.
